Healthcare Sector Analytics

Market size, company revenue, drug approvals, clinical trials, regulation, hospitals, doctors, drug spending, labs and devices

Brand drugFirst approved 2018

Lo-Zumandimine(Ethinyl Estradiol/Drospirenone)Aurobindo Pharma Limited logoAUROPHARMA.NS

Medicare prescription drug cost, prescriptions and prescribers, 2024 · made by Aurobindo Pharma Limited

$73K

Medicare cost, 2024

Medicare drug plans spent $72,652 on Lo-Zumandimine (ethinyl estradiol/drospirenone) in 2024, for 2,216 prescriptions and refills filled by 657 patients. Texas accounts for the most spending ($3,974, 5% of the total). It is made by Aurobindo Pharma Limited (AUROPHARMA.NS).

Medicare cost, 2024

$73K

+9.7% from 2023

Prescriptions

2,216

$32.79 per claim

Patients

657

703 prescribers

Total spending, 2024

$73K

$110.45 per patient

Questions and answers

How much does Medicare spend on Lo-Zumandimine?

Medicare prescription drug plans paid $73K for Lo-Zumandimine in 2024, for 2,216 prescriptions and refills to 657 patients (up 9.7% from 2023). The average cost per claim was $32.79.

Which state spends the most on Lo-Zumandimine?

Texas had the highest Medicare cost for Lo-Zumandimine in 2024: $3,974 for 113 claims, followed by Iowa ($3,785).

Who prescribes Lo-Zumandimine the most?

Celia L Andrews, nurse practitioner in Los Lunas, NM, had the highest Medicare cost for Lo-Zumandimine in 2024: 13 claims costing $738.

Who makes Lo-Zumandimine?

Lo-Zumandimine is made by Aurobindo Pharma Limited (AUROPHARMA.NS), listed in the Medicare spending data as Aurobindo Pharm.

Spending over the years

Medicare spending by year

All plans and makers

Prescriber data: cost by year

Medicare spending on Lo-Zumandimine was $73K in 2024, the highest year shown.

By state

Where the prescribers practice, 2024

Medicare cost by state

States with the highest cost

Top prescribers of Lo-Zumandimine, 2024

By Medicare drug cost

PrescriberTypeClaimsPatientsCost
Celia L Andrews Los Lunas, NMNurse Practitioner13Under 11$738
Katharine A Castillo Tucson, AZNurse Practitioner13Under 11$719
Steven S McPherson Franklin, LAInternal Medicine15Under 11$691
Lacy M Windham Cleveland, TNObstetrics & Gynecology22Under 11$595
Christy C Dunbar Leesville, SCNurse Practitioner16Under 11$569
Yoko Momoyama Lombard, ILInternal Medicine15Under 11$543
Melissa Redmond Maysville, KYNurse Practitioner12Under 11$464
Daniel L Hatch Fort Wayne, INNurse Practitioner13Under 11$449
Shari L Graham Cambridge, MNFamily Practice13Under 11$423
Rebecca M Knauf Sparta, MIPhysician Assistant11Under 11$368
Jasmine L Braman Lincoln, NENurse Practitioner11Under 11$364
Cala B Tanner Reidsville, GANurse Practitioner14Under 11$328
Keisha R Saunders Gary, WVNurse Practitioner13Under 11$305
Kelly Drescher Albuquerque, NMObstetrics & Gynecology15Under 11$291
Pamela M Hill Louisville, KYObstetrics & Gynecology14Under 11$259
Beth H Jelinek Cumberland, MDObstetrics & Gynecology16Under 11$248
Michael L Zorome Riverhead, NYFamily Practice14Under 11$217
Laura L Harbison Cameron, MOFamily Practice11Under 11$215
Madeleine J Hoffman Rifle, COPhysician Assistant13Under 11$165
Robert J Bruxvoort Holland, MIFamily Practice11Under 11$158
Denise Spence Amherst, MAInternal Medicine12Under 11$141
Soledad O Lee Buena Park, CAInternal Medicine13Under 11$141
Ashley J Wirtz Mosine, WIFamily Practice11Under 11$130
Rhonda K Darnell Benton, KYNurse Practitioner11Under 11$130
Virginia A Hardesty Leitchfield, KYNurse Practitioner11Under 11$130

Prescriber data by year

YearPrescribersClaimsPatientsCost
2022143355128$15K
20234991,519462$66K
20247032,216657$73K

Makers, 2024

Spending by manufacturer as listed in the spending data

ManufacturerClaimsSpending
Aurobindo PharmAUROPHARMA.NS logoAUROPHARMA.NS2,217$73K

Medicaid spending by quarter

Amount reimbursed by state Medicaid programs, all states

Amount reimbursed

Codes

National drug codes (packages)
2
RxNorm concept IDs
2003375, 630734, 748797, 748798
Application numbers
ANDA209632

More drugs: Medicare drug spending and the Prescriptions view.

Official US government data on Medicare prescription drug plans (Part D) and Medicaid drug use. Cost and spending are before the rebates drug makers pay. Prescribers with fewer than 11 claims of the drug are not published.

LinkedInLinkedInXXYouTubeYouTube